Trypanotoxic activity of thiosemicarbazone iron chelators

Ellis, Samuel, Sexton, Darren and Steverding, Dietmar (2015) Trypanotoxic activity of thiosemicarbazone iron chelators. Experimental Parasitology, 150. pp. 7-12. ISSN 1090-2449

[thumbnail of Accepted Version] Microsoft Word (Accepted Version) - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (198kB)

Abstract

Only a few drugs are available for treating sleeping sickness and nagana disease; parasitic infections caused by protozoans of the genus Trypanosoma in sub-Saharan Africa. There is an urgent need for the development of new medicines for chemotherapy of these devastating diseases. In this study, three newly designed thiosemicarbazone iron chelators, TSC24, Dp44mT and 3-AP, were tested for in vitro activity against bloodstream forms of T. brucei and human leukaemia HL-60 cells. In addition to their iron chelating properties, TSC24 and Dp44mT inhibit topoisomerase IIα while 3-AP inactivates ribonucleotide reductase. All three compounds exhibited anti-trypanosomal activity, with minimum inhibitory concentration (MIC) values ranging between 1 and 100 μM and 50% growth inhibition (GI50) values of around 250 nM. Although the compounds did not kill HL-60 cells (MIC values >100 μM), TSC24 and Dp44mT displayed considerable cytotoxicity based on their GI50 values. Iron supplementation partly reversed the trypanotoxic and cytotoxic activity of TSC24 and Dp44mT but not of 3-AP. This finding suggests possible synergy between the iron chelating and topoisomerase IIα inhibiting activity of the compounds. However, further investigation using separate agents, the iron chelator deferoxamine and the topoisomerase II inhibitor epirubicin, did not support any synergy for the interaction of iron chelation and topoisomerase II inhibition. Furthermore, TSC24 was shown to induce DNA degradation in bloodstream forms of T. brucei indicating that the mechanism of trypanotoxic activity of the compound is topoisomerase II independent. In conclusion, the data support further investigation of thiosemicarbazone iron chelators with dual activity as lead compounds for anti-trypanosomal drug development.

Item Type: Article
Uncontrolled Keywords: trypanosoma brucei,sleeping sickness,topoisomerase,thiosemicarbazone iron chelators,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Science
Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups: Faculty of Medicine and Health Sciences > Research Groups > Gastroenterology and Gut Biology
Depositing User: Pure Connector
Date Deposited: 04 Feb 2015 13:12
Last Modified: 21 Oct 2022 00:31
URI: https://ueaeprints.uea.ac.uk/id/eprint/52033
DOI: 10.1016/j.exppara.2015.01.004

Downloads

Downloads per month over past year

Actions (login required)

View Item View Item